HEPATITIS/HIV PROJECT NEWS
May 31, 2016 – A new fact sheet on Zepatier, and updated fact sheets on Solvaldi, Harvoni, Viekira Pak, and Daklinza now available for download.
Hepatitis C: No More Treatment Rationing; Universal Access to Generic Medicines Everywhere!
April 16, 2016, Barcelona, Spain – People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of lifesaving HCV medicines. They are pushing for generic competition to bring down the price of HCV treatment and ensure universal access.
TAGline Spring 2016
NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS
- Fair Pricing: Reclaiming Drugs for the Common Good
By Tim Horn
- Greed and the Necessity for Regulation
The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction
By Tim Horn, Erica Lessem, and Kenyon Farrow
- PrEP Pricing Problems
A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them
By James Krellenstein and Jeremiah Johnson
- The Low Cost of Universal Access
Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability
By Tracy Swan
mapCrowd: an online data collection platform for hepatitis C information
February 8, 2016 – Médecins du Monde (MdM) and Treatment Action Group (TAG) are pleased to announce the launch of mapCrowd (www.mapCrowd.org), an innovative online resource and data collection platform for gathering and sharing hepatitis C information.
HCV Fact Sheets in English and en Español
December 14, 2015 – This set of fact sheets include information on adherence to treatment, HCV diagnostics, and currently approved treatments (Sovaldi, Olysio, Viekira Pak and Technivie, Harvoni, Daklinza, and ribavirin).
Don’t forget treatment on World Hepatitis Day
July 28, 2015 — The prohibitive price of hepatitis C virus medications will result in needless deaths if we don’t act now
On World Hepatitis Day 2015, as the World Health Organization (WHO) emphasizes prevention, the International Treatment Preparedness Coalition (ITPC) and Treatment Action Group (TAG) urge pharmaceutical companies and the governments of middle-income countries (MICs) to act now to facilitate access to treatment for all people with hepatitis C virus (HCV), to avoid needless deaths from HCV complications and to prevent new infections.
2015 Pipeline Report
July 17, 2015 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development
Public Health Groups Sue FDA For Disclosure of Clinical Trial Data for Costly Hep C Drugs
June 25, 2015, New Haven, Connecticut – Treatment Action Group (TAG) and the Global Health Justice Partnership (GHJP) have filed a federal lawsuit to obtain access to the information that Gilead Sciences submitted to the FDA to obtain approval of two new—and extremely expensive—hepatitis C drugs, Sovaldi (sofosbuvir) and Harvoni (sofosvubir/ledipasvir). Hepatitis C affects at least 3 million people in the United States. Sovaldi and Harvoni significantly improve cure rates, but initial pricing was unprecedented: $84,000 and $94,500 for a 12-week course of treatment, respectively.
Gilead: Stop Blocking Access to Hepatitis C Treatment
Thousands of activists urge company to change its policies on eve of shareholder meeting
May 5, 2015, New York, New York – On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.
Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries (English, French, and Russian)
February 2, 2015 – This report presents a number of key strategies through real-world case studies and shows how strategies used to combat the AIDS epidemic can be—and have been—adapted to increase HCV treatment access. These strategies are introduced in three sections: Laying the groundwork through community organizing; overcoming the cost barriers to HCV treatment access; and collaborating with researchers to build your case for HCV treatment access.
Activists Urge Governor Cuomo to Reject Proposed NYS Medicaid HCV Treatment Restrictions
October 14, 2014 – As people living with or at risk for hepatitis C, their advocates, and care providers—and as New York State voters and taxpayers—we write to express our serious concerns about proposed Medicaid criteria that will limit access to sofosbuvir and other lifesaving hepatitis C medications. We urge you to reject these restrictive criteria and to support a comprehensive plan to end New York’s hepatitis C epidemic, as you have with HIV/AIDS.
Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug
July 24, 2014, Melbourne, Australia – Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C virus (HCV) drug. As Gregg Alton, Gilead’s Executive Vice President of Corporate and Medical Affairs, spoke, activists brought him a liver on a silver platter while chanting “Pills Cost Pennies, Greed Costs Lives,” “Shame, Shame, Shame,” and “Pharma Greed Kills.” Their signs said, “Wanted: Crimes Against Access,” “Hep C Criminal,” and “Gilead Kills” as the O’Jay’s “For the Love of Money” blared in the background.
2014 Pipeline Report
July 20, 2014 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
Read the HCV chapters online:
- Hepatitis C Pipeline: BONANZA! The Gold Rush Is Under Way
- 2013/2014 HCV Drug Pipeline Update
- Global Update: Hepatitis C Treatment Activism
1st Hepatitis C Virus World Community Advisory Board Report (Available in English, French, and Russian)
July 14, 2014 — The hepatitis C virus (HCV) World Community Advisory Board (CAB) grew from an international AIDS activist movement. The objectives of the meeting were three-fold: 1. To provide a forum for leading activists to learn about developments in HCV treatment and access barriers; 2. To find common advocacy strategies; and 3. To meet with pharmaceutical companies about their plans for low- and middle-income countries (LMICs).
New Hepatitis Resolution Is Passed at World Health Assembly; Challenges World Health Organization and Member States to Act
May 22, 2014, Geneva, Switzerland – Today, four years after introducing its first viral hepatitis resolution, the World Health Assembly (WHA)—the decision-making body of the World Health Organization (WHO)—passed the Hepatitis Resolution, which commits the WHO and United Nations (UN) member states to urgent action to address the global hepatitis pandemic, including that of hepatitis C virus (HCV).
Defuse Hepatitis C, the Viral Time Bomb: Test and Treat Hepatitis C
Position Paper for the 67th World Health Assembly, May 19–24, 2014
We, people living with HCV, HIV/AIDS, people who use drugs, and our advocates, urge United Nations (UN) Member States to act with urgency to end the hepatitis C epidemic; it is possible!
Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting
February 28, 2014, Bangkok, Thailand – Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for equitable access to treatment for HCV, a curable infection that kills over 350,000 people each year.
167 Organizations and 513 Individuals Signed on to Letter to Secretary Sebelius on the Allowance of Co-pay Assistance in the ACA Health Plans
December 2, 2013 – We, the undersigned organizations and individuals, are writing to urge that the HHS issue clear guidance on the allowance of drug industry–provided co-payment, co-insurance, or other out-of-pocket discount cards and coupons in the Affordable Care Act’s (ACA) Health Insurance Marketplaces. As people living with, and organizations serving people with, HIV, HCV, and other life-threatening and chronic health conditions, we are alarmed by the possibility of the prohibition of these critical financial lifelines in the ACA, just as affordable health insurance for people with preexisting conditions is finally becoming a reality in the United States, thanks to the ACA.
TRAINING MANUAL FOR TREATMENT ADVOCATES: Hepatitis C Virus and Coinfection with HIV
November 2013 – The information here is written by and for people who are not medical specialists. We are treatment activists who learned about hepatitis C because it was a problem for people in our communities. We designed it to help you understand basic information about hepatitis C and coinfection with HIV: how it is transmitted, how to prevent hepatitis C, how a person can find out if he or she has hepatitis C, what happens to both HIV-negative and HIV-positive people who have hepatitis C, information used for making treatment decisions, and treatment options.
135 Organizations Send Letter Urging UNITAID to Prioritize HIV/HCV Coinfection
October 10, 2013 – We commend UNITAID for addressing viral hepatitis in its 2013–2016 Strategic Objectives. We are writing to underscore the need for a swift response from UNITAID to hepatitis C virus (HCV) coinfection; delays will cost lives and impede scale-up when more effective and tolerable therapies are available.
Petition Drive: Demand Leadership from the World Health Organization to Defuse the Hepatitis C Viral Time Bomb
July 8, 2013 – Globally, approximately 185 million people are infected with the hepatitis C virus (HCV). Each year, 3–4 million people are newly infected, and 350,000 people die from HCV-related complications. The World Health Organization (WHO) has called hepatitis C a "viral time bomb," yet have done little to significantly address this global health crisis.
2013 Pipeline Report
June 30, 2013 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
Hepatitis C and the IL28B Gene Fact Sheet
April 2013 – This fact sheet describes how the genetic factor IL28B affects responses to hepatitis C treatment, including poorer efficacy among African Americans and people of African ancestry.
In September 2012, Médecins Sans Frontières, the Open Society Foundations, and Treatment Action Group, joined forces with activists, researchers, and UN and government representatives to identify priority issues, share information, and develop strategies to overcome the barriers that prevent access to HCV treatment in developing countries, both today and in the future.
Have a Heart, Save My Liver!
February 14, 2013 – Today, on the occasion of Valentine's Day, Médecins du Monde, and Treatment Action Group (TAG) are launching an action urging pharmaceutical giants Merck and Roche to drop their exorbitant prices for pegylated interferon, an effective hepatitis C (HCV) treatment. Send a Valentine’s Day card (download it at www.hepcoalition.org) to leadership at Merck and Roche and ask them to “Have a Heart, Save My Liver!”
Support Inclusion of Pegylated Interferon in the World Health Organization’s Essential Medicines List: Guidance for Civil Society Submissions
January 15, 2013 – Civil-society groups have an important but limited opportunity to advocate for the inclusion of pegylated interferon on the World Health Organization Essential Medicines List. Deadline Mid-February!
Guide to Clinical Trials for People with Hepatitis C (Second Edition)
January 2013 – There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated. Having more information can help you decide whether or not to participate in a clinical trial, and which trial, or trials, may be right for you. This guide is available in English and Spanish.
HCV Treatment Pipeline Update
December 12, 2012 – It is difficult to be anything other than dazzled by astounding cure rates of up to 100% from a multitude of interferon-free hepatitis C virus (HCV) clinical trials presented at the American Association for the Study of Liver Diseases (AASLD) meeting in November 2012. Proof of concept has been established: hepatitis C, a disease that claims more than 350,000 lives annually, can be cured with three months of oral antiviral drugs.
HCV Advocates Survey on Global Treatment Access
October 9, 2012 – Less toxic and more effective cures for hepatitis C virus (HCV) infection are being developed at a rapid pace. Unfortunately, these drugs are likely to be priced out of reach for the majority people who need it around the world. It will be up to activists to strategically fight for expanding access to life saving prevention, diagnostics, treatment and care. Please Click HERE to complete the short survey and tell us how we can support your current or planned advocacy work in this critical juncture.
Washington Call for Access to HCV Diagnostics, Treatment and Care for All!
July 27, 2012 – On the occasion of the XIX International Aids Conference in Washington, DC, USA, and the eve of World Hepatitis Day, the undersigned grassroots civil society groups and non-governmental organizations have formed an international coalition working towards universal access to HCV voluntary testing and treatment.
2012 Pipeline Report
HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development
July 22, 2012 – Visit our new website, www.PipelineReport.org, to:
Read the report online
Download individual chapters as PDFs
Browse for specific information by agent
HCAB Position Statement: Hepatitis C Drug Development and Drug-Drug Interaction Studies
February 2012 – The Hepatitis C Community Advisory Board (HCAB) recognizes the value of more effective and less toxic treatment for hepatitis C virus (HCV). We believe that sponsors can conduct key drug-drug interaction (DDI) studies with direct-acting antivirals (DAAs) and other candidates in development and medications commonly used by people with hepatitis C and those coinfected with HIV/HCV prior to their approval, without delaying development of these important therapies.
2011 Pipeline Report (Second Edition)
September 2011 – HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development
The Hepatitis C Treatment Pipeline Report
March 2011 – Interferon is the therapeutic backbone of hepatitis C virus (HCV) treatment, as well as the major barrier to HCV treatment access, uptake, and completion. For many people, hepatitis C treatment does not work, and side effects can be debilitating. Fortunately, scientific advances and keen interest from the pharmaceutical industry have led to the development of dozens of new oral antiviral drugs for hepatitis C. Hopefully, it will soon be possible to replace interferon with a combination of HCVspecific oral drugs (commonly referred to as direct-acting antivirals, or DAAs) that will work for everyone.
Guide to Hepatitis C for People Living with HIV - Testing, Coinfection, Treatment, and Support
October 2009 – Welcome to our treatment guide for HIV-positive people who also have the hepatitis C virus (called HCV, for short). The people who wrote this guide have direct experience with HIV and hepatitis C. We have written this guide to encourage you to explore the range of care and treatment choices available to you. We hope this information helps you feel more in control of some of your HCV treatment choices, so that you can focus on other things you want to do in life.
Guide to Hepatitis B for People Living with HIV
June 2009 – Welcome to this treatment guide for HIV-positive people who also have hepatitis B (HBV). This guide provides information on the prevention, care, and treatment of HBV, and the impact of HBV on HIV disease. It is designed to be accessible to people with no medical training. Where medical terms are used, they are explained in detailed but simple language.